Search Results - "Campelo, Rosario Garcia"

Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer by Camidge, D. Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James Chih-Hsin, Han, Ji-Youn, Lee, Jong-Seok, Hochmair, Maximilian J, Li, Jacky Yu-Chung, Chang, Gee-Chen, Lee, Ki Hyeong, Gridelli, Cesare, Delmonte, Angelo, Garcia Campelo, Rosario, Kim, Dong-Wan, Bearz, Alessandra, Griesinger, Frank, Morabito, Alessandro, Felip, Enriqueta, Califano, Raffaele, Ghosh, Sharmistha, Spira, Alexander, Gettinger, Scott N, Tiseo, Marcello, Gupta, Neeraj, Haney, Jeff, Kerstein, David, Popat, Sanjay

“…In a randomized trial involving patients with ALK -rearranged lung cancer, brigatinib was associated with longer progression-free survival and more activity…”
Get full text

New insights into molecular mechanisms of sunitinib-associated side effects by Aparicio-Gallego, Guadalupe, Blanco, Moisés, Figueroa, Angélica, García-Campelo, Rosario, Valladares-Ayerbes, Manuel, Grande-Pulido, Enrique, Antón-Aparicio, Luis

“…The introduction of targeted therapy represents a major advance in the treatment of tumor progression. Targeted agents are a novel therapeutic approach…”
Get full text

Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial by Camidge, D Ross, Kim, Hye Ryun, Ahn, Myung-Ju, Yang, James C H, Han, Ji-Youn, Hochmair, Maximilian J, Lee, Ki Hyeong, Delmonte, Angelo, Garcia Campelo, Maria Rosario, Kim, Dong-Wan, Griesinger, Frank, Felip, Enriqueta, Califano, Raffaele, Spira, Alexander I, Gettinger, Scott N, Tiseo, Marcello, Lin, Huamao M, Liu, Yuyin, Vranceanu, Florin, Niu, Huifeng, Zhang, Pingkuan, Popat, Sanjay

“…In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced…”
Get more information

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials by Ferrarotto, Renata, Anderson, Ian, Medgyasszay, Balazs, García‐Campelo, Maria Rosario, Edenfield, William, Feinstein, Trevor M., Johnson, Jennifer M., Kalmadi, Sujith, Lammers, Philip E., Sanchez‐Hernandez, Alfredo, Pritchett, Yili, Morris, Shannon R., Malik, Rajesh K., Csőszi, Tibor

“…Background Supportive care interventions used to manage chemotherapy‐induced myelosuppression (CIM), including granulocyte colony‐stimulating factors (G‐CSFs),…”
Get full text

Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy by Campelo, Rosario García, Figueroa, Angélica, Pulido, Enrique Grande, Aparicio, Luís Antón, Calvo, Moisés Blanco

“…Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number of transporter proteins to…”
Get full text

Improving quality of care by standardising patient data collection in electronic medical records in an oncology department in Spain by Alonso-Jáudenes Curbera, Guillermo, Gómez-Randulfe Rodríguez, Martín Igor, Alonso de Castro, Beatriz, Silva Díaz, Sofía, Parajó Vázquez, Iria, Gratal, Paula, López López, Rafael, García Campelo, Rosario

“…BackgroundEvaluation of quality of care in oncology is key in ensuring patients receive adequate treatment. American Society of Clinical Oncology’s (ASCO)…”
Get full text

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis by García Campelo, María Rosario, Arriola, Edurne, Campos Balea, Begoña, López-Brea, Marta, Fuentes-Pradera, José, de Castro Carpeno, Javier, Aguado, Carlos, Pérez Parente, Diego, de Oro Pulido, Fidel, Ruiz-Gracia, Pedro, Rodríguez-Abreu, Delvys

“…This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared…”
Get full text

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial by Laza‐Briviesca, Raquel, Cruz‐Bermúdez, Alberto, Nadal, Ernest, Insa, Amelia, García‐Campelo, María del Rosario, Huidobro, Gerardo, Dómine, Manuel, Majem, Margarita, Rodríguez‐Abreu, Delvys, Martínez‐Martí, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé Caro, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Viteri, Santiago, Massuti, Bartomeu, Casarrubios, Marta, Sierra‐Rodero, Belén, Tarín, Carlos, García‐Grande, Aránzazu, Haymaker, Cara, Wistuba, Ignacio I., Romero, Atocha, Franco, Fernando, Provencio, Mariano

“…Background Immunotherapy is being tested in early‐stage non‐small cell lung cancer (NSCLC), and achieving higher rates of complete pathological responses (CPR)…”
Get full text

Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors by Nadal, Ernest, Massuti, Bartomeu, Dómine, Manuel, García-Campelo, Rosario, Cobo, Manuel, Felip, Enriqueta

“…Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–programmed cell death ligand-1 (PD-L1) axis have shown promising results in…”
Get full text

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy by Casarrubios, Marta, Provencio, Mariano, Nadal, Ernest, Insa, Amelia, del Rosario García-Campelo, María, Lázaro-Quintela, Martín, Dómine, Manuel, Majem, Margarita, Rodriguez-Abreu, Delvys, Martinez-Marti, Alex, De Castro Carpeño, Javier, Cobo, Manuel, López Vivanco, Guillermo, Del Barco, Edel, Bernabé, Reyes, Viñolas, Nuria, Barneto Aranda, Isidoro, Massuti, Bartomeu, Sierra-Rodero, Belén, Martinez-Toledo, Cristina, Fernández-Miranda, Ismael, Serna-Blanco, Roberto, Romero, Atocha, Calvo, Virginia, Cruz-Bermúdez, Alberto

“…BackgroundNeoadjuvant chemoimmunotherapy for non-small cell lung cancer (NSCLC) has improved pathological responses and survival rates compared with…”
Get full text

MET alterations in NSCLC-Current Perspectives and Future Challenges by Remon, Jordi, Hendriks, Lizza E L, Mountzios, Giannis, García-Campelo, Rosario, Saw, Stephanie P L, Uprety, Dipesh, Recondo, Gonzalo, Villacampa, Guillermo, Reck, Martin

“…Targeted therapies have revolutionized the treatment and improved the outcome for oncogene-driven NSCLC and an increasing number of oncogenic driver therapies…”
Get more information

Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges by Mountzios, Giannis, Remon, Jordi, Hendriks, Lizza E. L., García-Campelo, Rosario, Rolfo, Christian, Van Schil, Paul, Forde, Patrick M., Besse, Benjamin, Subbiah, Vivek, Reck, Martin, Soria, Jean-Charles, Peters, Solange

“…Therapeutic strategies harnessing the immune system to eliminate tumour cells have been successfully used for several cancer types, including in patients with…”
Get full text

Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis by Gomez-Randulfe, Igor, Silva Díaz, Sofía, Escriu, Carles, Mohammed, Saara, Shah, Riyaz, Benitez Fuentes, Javier David, Cox, Samantha, Monaca, Federico, Bria, Emilio, García-Campelo, María Rosario, Crook, Benjamin, Talbot, Toby, Leporati, Rita, Balachandran, Kirsty, Newsom-Davis, Tom, Hughes, Sarah, Cove-Smith, Laura, Taylor, Paul, Blackhall, Fiona, Califano, Raffaele

“…Second-line treatment for small-cell lung cancer (SCLC) is primarily guided by the time elapsed since the last platinum dose. Rechallenge with carboplatin and…”
Get full text

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer by Rosell, Rafael, Moran, Teresa, Queralt, Cristina, Porta, Rut, Cardenal, Felipe, Camps, Carlos, Majem, Margarita, Lopez-Vivanco, Guillermo, Isla, Dolores, Provencio, Mariano, Insa, Amelia, Massuti, Bartomeu, Gonzalez-Larriba, Jose Luis, Paz-Ares, Luis, Bover, Isabel, Garcia-Campelo, Rosario, Moreno, Miguel Angel, Catot, Silvia, Rolfo, Christian, Reguart, Noemi, Palmero, Ramon, Sánchez, José Miguel, Bastus, Roman, Mayo, Clara, Bertran-Alamillo, Jordi, Molina, Miguel Angel, Sanchez, Jose Javier, Taron, Miquel

“…Lung cancers with a mutation in the EGFR gene have heightened sensitivity to tyrosine kinase inhibitors. Asian patients have been the most intensively studied…”
Get full text

Proceedings from the First Onco Summit: LATAM Chapter, 19-20 May 2023, Rio de Janeiro, Brazil by Hungria, Vania, Sureda, Anna, Campelo, Garcia Rosario, Salvino, Marco Aurélio, Ramasamy, Karthik

“…The Onco Summit 2023: The Latin American (LATAM) Chapter took place over two days, from 19-20 May 2023, in Brazil. The event aimed to share the latest updates…”
Get full text

DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy by Filippi, Andrea R, Dziadziuszko, Rafał, García Campelo, Maria Rosario, Paoli, Jean-Baptiste, Sawyer, William, Díaz Pérez, Ignacio Esteban

“…Consolidation durvalumab is standard of care in patients with unresectable, stage III non-small-cell lung cancer (NSCLC) without disease progression following…”
Get full text

Lung Cancer in Spain by Remon, Jordi, Reguart, Noemí, García-Campelo, Rosario, Conde, Esther, Lucena, Carmen-María, Persiva, Oscar, Navarro-Martin, Arturo, Rami-Porta, Ramón

Get more information

SEOM-GECP Clinical guidelines for diagnosis, treatment and follow-up of small-cell lung cancer (SCLC) (2022) by García-Campelo, Rosario, Sullivan, Ivana, Arriola, Edurne, Insa, Amelia, Juan Vidal, Oscar, Cruz-Castellanos, Patricia, Morán, Teresa, Reguart, Noemí, Zugazagoitia, Jon, Dómine, Manuel

“…Small-cell lung cancer (SCLC) is a highly aggressive malignancy comprising approximately 15% of lung cancers. Only one-third of patients are diagnosed at…”
Get full text

Immune-Related Adverse Events and Corticosteroid Use for Cancer-Related Symptoms Are Associated With Efficacy in Patients With Non-small Cell Lung Cancer Receiving Anti-PD-(L)1 Blockade Agents by Riudavets, Mariona, Mosquera, Joaquin, Garcia-Campelo, Rosario, Serra, Jorgina, Anguera, Georgia, Gallardo, Pablo, Sullivan, Ivana, Barba, Andrés, del Carpio, Luís, Barnadas, Agustí, Gich, Ignasi, Majem, Margarita

“…Background: Immune-related adverse events (irAEs) have been associated with improved efficacy in advanced non-small cell lung cancer (NSCLC) patients receiving…”
Get full text

Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer by Janik, Adrianna, Torrente, Maria, Costabello, Luca, Calvo, Virginia, Walsh, Brian, Camps, Carlos, Mohamed, Sameh K, Ortega, Ana L, Nováček, Vít, Massutí, Bartomeu, Minervini, Pasquale, Campelo, M Rosario Garcia, Del Barco, Edel, Bosch-Barrera, Joaquim, Menasalvas, Ernestina, Timilsina, Mohan, Provencio, Mariano

“…Stratifying patients with cancer according to risk of relapse can personalize their care. In this work, we provide an answer to the following research…”
Get more information